1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Solid Tumor Testing Market in the US 2016-2020

Solid Tumor Testing Market in the US 2016-2020

  • February 2016
  • -
  • Infiniti Research Limited
  • -
  • 50 pages

About Solid Tumor Testing Market in the US

Solid tumor testing or screening is done for the early detection of cancer, enabling effective treatment measures to avoid the spread of cancerous cells throughout the body. The testing procedure involves testing of samples such as urine, blood, and other bodily substances. Further, cancer testing also involves conducting genetic tests to analyze certain gene mutations that are linked to certain cancer types. Biopsy, colonoscopy, Papanicolaou (Pap) test, and fecal occult blood tests are some of the tests that are performed for cancer screening.

Technavio’s analysts forecast the solid tumor testing market in the US to grow at a CAGR of 11.1% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the solid tumor testing market in the US for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of solid tumor testing products, such as assays or kits and bench-top instruments.

The market is divided into the following segments based on cancer types:
- Breast cancer
- Lung cancer
- Colorectal cancer
- Prostate cancer
- Cervical cancer
- Other (including pancreatic cysts and thyroid nodules)

Technavio's report, Solid Tumor Testing Market in the US 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendorsoperating in this market.

Key vendors
- Abbott Molecular
- Agilent Technologies (Dako)
- Beckman Coulter
- Roche Diagnostics


Other prominent vendors
- 20/20 GeneSystems
- Adaptive Biotechnologies
- Advanced Cell Diagnostics
- Affymetrix
- Agena Bioscience
- Ambry Genetics
- ApoCell
- Avant Diagnostics
- Biological Dynamics
- Boditech Med
- Becton, Dickinson and Company (BD)
- Biocare Medical
- Bio-Rad Laboratories
- Castle Biosciences
- CDx Diagnostics
- Celerus Diagnostics
- Cancer Genetics
- Caris Life Sciences
- Clarient Diagnostic Services
- DiaTech Oncology
- Enzo Biochem
- Epic Sciences
- EDP Biotech
- Eutropics Pharmaceuticals
- Fujirebio Diagnostics
- Genalyte
- Hologic
- Janssen Diagnostics
- Myriad Genetics
- Omnyx
- OxfordGene Technology
- Oncospire Genomics
- OncoCyte
- OvaGene Oncology
- Pathway Genomics
- Quest Diagnostics
- QIAGEN
- RiboMed Biotechnologies
- Sequenom
- Siemens Healthcare Diagnostics
- Thermo Fisher Scientific
- Tosoh Bioscience
- TrimGen

Market driver
- High demand for personalized medicines
- For a full, detailed list, view our report

Market challenge
- Regulatory issues
- For a full, detailed list, view our report

Market trend
- Ready-to-use reagents
- For a full, detailed list, view our report

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

Table Of Contents

Solid Tumor Testing Market in the US 2016-2020
PART 01: Executive summary
- Highlights
PART 02: Scope of the report
- Market overview
- Top-vendor offerings
PART 03: Market research methodology
- Research methodology
- Economic indicators
PART 04: Introduction
- Key market highlights
PART 05: Healthcare reform in US
- Impact of US healthcare reform on cancer testing industry
PART 06: Reimbursement and coverage: An overview
- Current scenario: Validating diagnostic tests
- Reimbursement structure in US
- Prevailing issues of reimbursement policies
PART 07: Market landscape
- Market overview
- Market size and forecast
- Five forces analysis
PART 08: Market segmentation by technology
- Conventional testing
- Genetic testing
PART 09: Market segmentation by cancer type
- Breast cancer
- Lung cancer
- Colorectal cancer
- Prostate cancer
- Cervical cancer
- Other
PART 10: Market drivers
- High demand for personalized medicines
- Changes in healthcare system
- Rise in demand for POC testing
- Increase in molecular testing
PART 11: Impact of drivers
PART 12: Market challenges
- Shortage of accurate cancer testing kits
- Regulatory issues
- Lack of skilled technicians
PART 13: Impact of drivers and challenges
PART 14: Market trends
- Use of bench-top mass spectrometer
- Ready-to-use reagents
PART 15: Vendor landscape
- Competitive scenario
- Key vendor analysis 2015
- Other prominent vendors
PART 16: Appendix
- List of abbreviations
PART 17: Explore Technavio


List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: US healthcare infrastructure before and after healthcare reform
Exhibit 03: Positive and negative impact of US healthcare reform on market
Exhibit 04: Reimbursement perspectives of healthcare entities
Exhibit 05: Solid tumor testing market in US
Exhibit 06: Solid tumor testing market in US 2015-2020 ($ billions)
Exhibit 07: Five forces analysis
Exhibit 08: Segmentation of solid tumor testing market in US by technology 2015
Exhibit 09: Segmentation of solid tumor testing market in US by technology 2020
Exhibit 10: Segmentation of solid tumor testing market in US by technology 2015-2020
Exhibit 11: Solid tumor conventional testing market in US 2015-2020 ($ billions)
Exhibit 12: Solid tumor genetic testing market in US 2015-2020 ($ billions)
Exhibit 13: Segmentation of solid tumor testing market in US by cancer type
Exhibit 14: Segmentation of solid tumor testing market in US by cancer type 2015
Exhibit 15: Segmentation of solid tumor testing market in US by cancer type 2020
Exhibit 16: Segmentation of solid tumor testing market in US by cancer type 2015-2020
Exhibit 17: Solid tumor testing market in US for breast cancer 2015-2020 ($ billions)
Exhibit 18: Solid tumor testing market in US for lung cancer 2015-2020 ($ billions)
Exhibit 19: Solid tumor testing market in US for colorectal cancer 2015-2020 ($ billions)
Exhibit 20: Solid tumor testing market in US for prostate cancer 2015-2020 ($ millions)
Exhibit 21: Solid tumor testing market in US for cervical cancer 2015-2020 ($ millions)
Exhibit 22: Solid tumor testing market in US for other cancers 2015-2020 ($ millions)
Exhibit 23: Impact of drivers
Exhibit 24: Impact of drivers and challenges
Exhibit 25: Abbott Molecular: Key takeaways
Exhibit 26: Agilent Technologies (Dako): Key takeaways
Exhibit 27: Beckman Coulter: Key takeaways
Exhibit 28: Roche Diagnostics: Key takeaways

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Hematological Cancers: Analytical Tool

Hematological Cancers: Analytical Tool

  • $ 11505
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

  • $ 6995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation Summary Glioblastoma multiforme (GBM) is a grade IV tumor that arises from astrocytes. It is ...

Lung Cancer: Analytical Tool

Lung Cancer: Analytical Tool

  • $ 8096
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Ovarian Cancer: Analytical Tool

August 2016 $ 8096

Renal Cancer: Analytical Tool

August 2016 $ 8096

Bladder Cancer: Analytical Tool

August 2016 $ 8096

Brain Cancer: Analytical Tool

August 2016 $ 8096

Breast Cancer: Analytical Tool

August 2016 $ 8096

Download Unlimited Documents from Trusted Public Sources

Cancer Statistics in the US - Forecast

  • November 2016
    4 pages
  • Cancer  

  • United States  

    New Zealand  

View report >

Cancer Statistics in the UK

  • November 2016
    51 pages
  • Cancer  

    Therapy  

    Oncology  

  • United Kingdom  

    Europe  

View report >

Cancer Statistics in the US

  • November 2016
    8 pages
  • Cancer  

  • United States  

View report >

Related Market Segments :

Cancer

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.